The filing confirms, rather than changes, the existing earnings outlook. Humana will reaffirm FY 2026 guidance of at least $6.52 in GAAP EPS and at least $9.00 in adjusted EPS, explicitly matching the guidance issued July 29, 2026. 〔0〕 Because the direction was already public, this is a confirmation event—not a new earnings signal—and lands as in line with the standing expectation.
| FY 2026 measure | Guidance |
|---|---|
| GAAP diluted EPS | At least $6.52 (EPS reconciliation) |
| Amortization of identifiable intangibles | $0.30 (EPS reconciliation) |
| Put/call valuation adjustments | $1.47 (EPS reconciliation) |
| Value creation initiatives | $1.27 (EPS reconciliation) |
| Impairment charges | $0.17 (EPS reconciliation) |
| Cumulative net tax impact | $(0.73) (EPS reconciliation) |
| Adjusted diluted EPS | At least $9.00 (EPS reconciliation) |
The adjusted target is stable, but GAAP earnings retain more uncertainty. Management says it does not expect changes to the adjusted EPS outlook, while potential GAAP changes remain possible because of ongoing value-creation and other strategic initiatives. 〔1〕 〔2〕 That distinction leaves the core operating outlook steady but preserves volatility around accounting items and strategic actions.
The next material information point is Medicare Advantage quality performance, not this filing. Humana will not discuss 2027 MA Star Ratings until CMS releases final data in October 2026. 〔3〕 With no guidance increase, cut, or new operating data here, the net read is a routine reaffirmation and the market’s attention shifts to that October release.
Read the original 8-K on SEC EDGAR ↗